Registry assessing PSMA PET outcomes in prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the prognostic value of Prostate-Specific Membrane Antigen (PSMA) PET imaging in patients with prostate cancer. It will compare the outcomes of PSMA PET with established clinical prognostic scores across various stages of the disease. The study will include adult patients who have undergone PSMA PET for staging or re-staging and have at least three years of follow-up data available. The findings could enhance risk assessment and management strategies for prostate cancer patients.

Why it matters

Who can join: the full rules

Inclusion:

* Adult patients with
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.

Exclusion:

* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer.

Where it's running

• University Hospital Essen
  Essen, Germany Recruiting

Study contacts

• Principal investigator: Wolfgang P Fendler, M.D. — University Hospital, Essen
• Study coordinator: Wolfgang P Fendler, M.D.
• Email: redcap@ikim.nrw
• Phone: +492017232032

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-XACP3 PET/CT for detecting prostate cancer lesions

  This study will test whether 68Ga-XACP3 PET/CT can find tumor lesions in adults with prostate cancer or suspected recurrence compared with the standard 68Ga-PSMA PET/CT.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07242014

• Virtual Sexual Health and Rehabilitation eClinic for Prostate Cancer Patients

  This study is testing a virtual clinic that helps prostate cancer patients and their partners manage sexual health issues after treatment to see if it improves their sexual function and relationship satisfaction.

  Recruiting at 6 sites University Health Network, Toronto · Vancouver, British Columbia and 9 other locations · NCT06877598

• Comparing two PET imaging agents for prostate cancer diagnosis

  This study is testing a new PET imaging agent for prostate cancer to see if it works better than an existing one in diagnosing the disease and spotting any spread or recurrence.

  Recruiting Early Phase 1 Anhui Provincial Hospital · Hefei, Anhui · NCT06756334

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.